Biomarker Discovery for Treatment of Diabetes

A biomarker is defined as “any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease”.For the purpose of predicting type 1 diabetes, a biomarker should be present in a subset of the population, and this subset should have a bias in the proportion of people in whom type 1 diabetes develops. A biomarker should also present a quantifiable risk for the development of type 1 diabetes within a defined period or diagnose a “stage” in the progression to clinical or symptomatic type 1 diabetes. As described in this article, most of the biomarkers used for the prediction of type 1 diabetes are islet-specific supporting the concept that, before overt hyperglycemia, type 1 diabetes is predominantly a targeted disease rather than a systemic disease.
Atomic Biomarkers can be separated as "a trademark that is precisely measured and gaged as a pointer of typical natural methods, pathogenic methodology, or pharmacologic reactions to a pharmaceutical intercession.
Biomarkers have fundamental influence in driving clinical trials and treating patients. Progresses in sub-atomic diagnostics help medicinal experts make proficient, experimentally legitimate choices. All the more efficient disclosure and use of biomarkers in the development of antidiabetes medications will rely on upon quickening our comprehension of the pathogenesis of diabetes and particularly its macrovascular entanglements. Procedural upgrades from different fields, particularly tumor, are starting to demonstrate the way towards better models of diabetes pathogenesis and atomic biomarker revelation.

  • Prognostic marker
  • Diabetic nephropathy marker
  • Molecular marker for metabolic syndrome
  • Molecular Marker-Hypoglycemic response
  • Inflammatory markers: Type 2 diabetes
  • Pharmacotherapy in treatment of diabetes

Related Conference of Biomarker Discovery for Treatment of Diabetes

June 15-16, 2020

29th European Diabetes Congress

Barcelona, Spain
June 23-24, 2020

29th World Diabetes & Heart Congress

Tokyo, Japan
July 15-16, 2020

3rd Global Diabetes Summit

Helsinki, Finland
July 15-16, 2020

28th International Diabetes and Healthcare Conference

Helsinki, Finland
July 20-21, 2020

Annual Congress on Diabetes, Metabolism and Obesity

Manila, Philippines
August 17-18, 2020

16th World Congress on Endocrinology & Diabetes

Copenhagen, Denmark
August 17-18, 2020

World Congress on Endocrinology and Metabolic Syndrome

Bangkok, Thailand
August 24-25, 2020

Global Summit on Diabetes & Endocrinology

Kyoto, Japan
August 24-25, 2020

Annual Summit on Diabetes and Endocrinology

Barcelona, Spain
September 21-22, 2020

Annual Congress on Endocrinology, Diabetes and Healthcare

Bangkok, Thailand
September 22-23, 2020

2nd Asia Pacific Endocrinology Congress

Singapore City, Singapore
September 28-29, 2020

4th Annual Congress on Diabetes, Obesity and Its Complications

Singapore City, Singapore
October 04-05, 2020

World Summit on Blood Glucose Monitoring

Beijing, China
October 07-08, 2020

International Summit on Diabetes

Barcelona, Spain
October 14-15, 2020

World Congress on Endocrinology & Diabetes

Rome, Italy
October 14-15, 2020

Global Congress on Endocrinology and Gynecology

Sydney, Australia
October 30-31, 2020

Annual Summit on Metabolomics

Vancouver, Canada
November 09-10, 2020

International Congress and Expo on Diabetic Care

Bangkok, Thailand
November 13-14, 2020

International Conference on Diabetes and Heart Diseases

Bangkok, Thailand
November 16-17, 2020

World Congress and Expo on Diabetes

Kyoto, Japan
November 16-17, 2020

2nd Asia Pacific Diabetes and Endocrinology Congress

Brisbane, Australia
November 18-19, 2020

Annual congress on Diabetes and Endocrinology Congress

Bangkok, Thailand
December 07-08, 2020

13th World Congress on Endocrinology and Metabolic Disorders

Auckland, Newzealand

Biomarker Discovery for Treatment of Diabetes Conference Speakers